1 2 3	The impact of colectomy and chemotherapy on risk of type 2 diabetes onset in patients with colorectal cancer: Nationwide cohort study in Denmark
4	Caroline Elisabeth Krag <sup>1,2*</sup> , Maria Saur Svane <sup>1,3*</sup> , Sten Madsbad <sup>1</sup> , Susanne Boel Graversen <sup>8</sup> , Jesper
5	Frank Christensen <sup>4,5,6</sup> , Thorkild IA Sørensen <sup>7,</sup> Louise Lang Lehrskov <sup>4*</sup> , Tinne Laurberg <sup>8*</sup>
6	*shared authors
7	
8	Affiliations
9 10	<sup>1</sup> Department of Endocrinology, Copenhagen University Hospital Hvidovre, 2650 Hvidovre, Denmark.
11 12	<sup>2</sup> Department of Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, 2200 Copenhagen, Denmark.
13	<sup>3</sup> Department of Surgical Gastroenterology, Copenhagen University Hospital Hvidovre, 2650
14	Hvidovre, Denmark
15 16	<sup>4</sup> Centre for Physical Activity Research, Copenhagen University Hospital - Rigshospitalet, Copenhagen, 2100 Copenhagen, Denmark.
17 18 19 20	<ul> <li><sup>5</sup> Department of Sports Science and Clinical Biomechanics, Faculty of Health Sciences, University of Southern Denmark, 5000 Odense, Denmark</li> <li><sup>6</sup> Digestive Disease Center, Bispebjerg Hospital, 2400 Copenhagen, Denmark</li> <li><sup>7</sup> Novo Nordisk Foundation Center for Basic Metabolic Research and Department of Public Health,</li> </ul>
21	University of Copenhagen, 2200 Copenhagen, Denmark.
22 23	<sup>8</sup> Steno Diabetes Center Aarhus, Aarhus University Hospital, 8200 Aarhus, Denmark.
24 25 26 27 28 29 30 31	Corresponding Author: Louise Lang Lehrskov, MD, PhD The Centre for Physical Activity Research (CFAS), Blegdamsvej 9, DK-2100 Copenhagen, Denmark Fax 45 35 45 76 44 Email: louise.lang.lehrskov.01@regionh.dk http://aktivsundhed.dk
32	
33 24	<b>Running title:</b> KRAG et al: COLORECTAL CANCER TREATMENT AND ONSET OF TYPE 2
34 35	DIABETES
36	
37	Word count: 3112
38	Figures: 2
39	Tables: 4

It is made available under a CC-BY-NC-ND 4.0 International license .

- 40 **References**: 35
- 41 **Key words:** Colorectal cancer, surgery, chemotherapy, type 2 diabetes
- 42
- 43 Impact statement: Colon cancer treatment per se can affect type 2 diabetes risk, but bmi at time of 44 surgery holds the strongest association.
- 45

46 Abstract

# 47 Background

- 48 Comorbidity with type 2 diabetes (T2D) results in worsening of cancer-specific and overall
- 49 prognosis in colorectal cancer (CRC) patients. The treatment of CRC *per se* may be diabetogenic.
- 50 We assessed the impact of different types of surgical cancer resections and oncological treatment on
- 51 risk of T2D development in CRC patients.

# 52 Method

53 We developed a population-based cohort study including all Danish CRC patients, who had

- 54 undergone CRC surgery between 2001-2018. Using nationwide register data, we identified and
- 55 followed patients from date of surgery and until new-onset of T2D, death or end of follow-up.

# 56 Results

- 57 In total, 46,373 CRC patients were included and divided into six groups according to type of
- 58 surgical resection: 10,566 Right-No-Chemo (23%), 4,645 Right-Chemo (10%), 10,151 Left-No-
- 59 Chemo (22%), 5,257 Left-Chemo (11%), 9,618 Rectal-No-Chemo (21%) and 6,136 Rectal-Chemo
- 60 (13%). During 245,466 person-years of follow-up 2,556 patients developed T2D. The incidence
- rate (IR) of T2D was highest in the Left-Chemo group 11.3 (95%CI: 10.4-12.2) per 1,000 person-
- 62 years and lowest in the Rectal-No-Chemo group 9.6 (95%CI: 8.8-10.4). Between-group unadjusted
- 63 hazard ratio (HR) of developing T2D was similar and non-significant. In the adjusted analysis,
- 64 Rectal-No-Chemo was associated with lower T2D risk (HR 0.86 [95%CI 0.75-0.98]) compared to
- 65 Right-No-Chemo.
- 66 For all six groups, an increased level of BMI resulted in a nearly twofold increased risk of
- 67 developing T2D
- 68 Conclusion
- 69 This study suggests postoperative T2D screening should be prioritized in CRC survivors with
- 70 overweight/obesity regardless of type of colorectal cancer treatment applied.

# 71 Funding

72 The Novo Nordisk Foundation (*NNF17SA0031406*); TrygFonden (101390; 20045; 125132).

It is made available under a CC-BY-NC-ND 4.0 International license .

#### 73 Introduction

74 Colorectal cancer (CRC) is the third most common cancer worldwide, <sup>1</sup> and the incidence rate is still increasing.<sup>2</sup> The same applies to the global incidence rate of type 2 diabetes (T2D). The 75 association between CRC and T2D is well-established, as patients with T2D have approximately 76 77 30% increased risk of developing CRC,<sup>3</sup> and T2D is known to negatively influence the prognosis of CRC.<sup>4</sup> Furthermore, some studies even show an increased T2D risk in CRC survivors.<sup>5,6</sup> 78 79 Fortunately, survival after a CRC diagnosis is steadily improving due to early detection, diagnostic 80 precision, and more advanced cancer treatment; and today, more than 70% of non-metastatic CRC patients are alive after 5 years.<sup>7</sup> Accordingly, it becomes increasingly important to identify CRC 81 82 patients at risk of developing long-term health problems like T2D in order to initiate preventive

strategies or treatment. <sup>6</sup> The underlying mechanisms behind the increased T2D risk in CRC
survivors are poorly understood. However, shared life-style related risk factors such as obesity,
physical inactivity, and unhealthy diet may play a role. <sup>8-10</sup>

Another explanation may be treatment-induced hyperglycemia. Prior studies showed that treatment 86 with adjuvant chemotherapy can induce hyperglycemia and development of T2D in CRC patients. 87 <sup>6,11,12</sup> Moreover, glucocorticoid, administered to alleviate side effects of chemotherapy, may impair 88 glucose homeostasis and thus increase the risk of T2D.<sup>13,14</sup> In addition to the drug-induced 89 metabolic disturbances, a recent study revealed that the type of CRC surgery per se is associated 90 with diverging risk of T2D.<sup>15</sup> A previous nationwide Danish study revealed that patients, who had 91 92 undergone left-sided colon resection for CRC and other colonic illnesses had an increased risk of 93 developing T2D, whereas this risk was unaltered in patients who had undergone right-sided colonic resections compared with a control group.<sup>15</sup> However, this study lacks essential information on the 94 95 role of potential modifying factors like BMI, treatment with chemotherapy etc. Along the same line, 96 in a population of non-CRC patients, Lee et al. published that patients who had undergone right-97 sided or transversal colonic resections had a reduced risk of developing T2D compared with a matched non-colectomy control group.<sup>16</sup> These findings raise an intriguing question of whether the 98 99 risk of developing T2D in CRC survivors may be casually affected by the type of CRC surgery. 100 Possible explanations of this side-specific risk modification include removal of different 101 enteroendocrine cell types resulting in gut changes that is important for insulin secretion and action 102 and for appetite regulation as well as changes in the microbiome, but causality remains to be investigated further. 17-19 103

It is made available under a CC-BY-NC-ND 4.0 International license .

105 In the present study, we tested the hypothesis whether different types of surgical cancer resection

106 and oncological treatment have an impact on risk of developing diabetes in CRC survivors. For this

107 purpose, we used a nationwide register to compare the frequency of diabetes development in CRC

108 patients who had undergone right-sided colectomy, left-sided colectomy or rectal resection with and

- 109 without chemotherapy, when adjusting for potential modifying factors like BMI etc.
- 110

# 111 Methods and material

# 112 Study population

113 The study was based on information from Danish nationwide health registers. All data are recorded 114 with reference to a civil registration number, which is a unique personal identification number 115 assigned to all Danish residents. This number permits accurate linkage of recorded information at 116 the personal level.<sup>20</sup>

117

The study population was identified through the Danish Colorectal Cancer Group (DCCG) database, which contains prospectively collected and validated data on all patients with CRC since 2001, including data on patient's characteristics, diagnostics and treatment.<sup>21</sup> The degree of patient inclusion in the database is high (>95%) and thus adequately represents the population of Danish CRC patients undergoing anti-cancer resections.<sup>21</sup>

123

We included all CRC cancer patients undergoing cancer surgery between 1<sup>st</sup> of May 2001 until 31<sup>st</sup> of December 2018 (Figure 1). Patients with unspecified surgery or total colectomy were excluded as these procedures are not standard treatment for CRC. Additionally, individuals diagnosed with Type 1 diabetes (T1D) either before or after surgery were excluded, along with those diagnosed with T2D preoperatively or within the first 2 weeks postoperatively, as the last group probably represents patients with preoperatively unknown pre-existing prediabetes or diabetes.

130 22

#### 131 Exposure

Patients were subdivided into six groups according to the surgical procedure and whether the patients had received chemotherapy or not. The group "right-sided colonic resection" (Right) included patients with cancer in coecum, ascending colon, or the oral part of colon transversum, the group "left-sided colonic resection" (Left) included patients with cancer in the anal part of colon transversum, descending colon, and sigmoid colon, and the group "rectal resection" (Rectal)

It is made available under a CC-BY-NC-ND 4.0 International license .

137 included patients with rectal cancer. Information regarding chemotherapy was limited to whether

138 the patient had received chemotherapy (Chemo) or not (No-Chemo).

139 Based on the combination of surgical procedures and chemotherapy, the study population was

- 140 divided into six groups: Right-No-Chemo, Right-Chemo, Left-No-Chemo, Left-Chemo, Rectal-No-
- 141 Chemo, Rectal-Chemo.

142 Radiation therapy is only part of standard treatment for rectal cancer, and therefore this oncological

- 143 modality was restricted to Rectal patients (Rectal-No-Radiation vs. Rectal-Radiation).
- Finally, a sub analysis was made comparing all colonic resected patients (All Colon) with all rectalresected (All Rectal)
- 146

# 147 **Outcome**

148 The primary outcome was first-time diagnosis of T2D after different types of CRC cancer surgery 149 and chemotherapy. Patients were followed from date of surgery until time to T2D diagnosis, 150 emigration, death, or the end of follow up (31<sup>st</sup> of December 2018), whichever came first.

151 Individuals with T2D were identified from data in the Danish National Patient Register (comprising 152 information on diagnoses during all hospital contacts in Denmark), the National Prescription 153 Registry (comprising information on all prescriptions filled at any pharmacy in Denmark), and the Danish National Health Service Register (comprising information on podiatrist services) as 154 described by Carstensen et al.<sup>22</sup> Diabetes is defined as the second occurrence of any event across 155 156 three types of inclusion events: 1) Diabetes diagnosed during hospitalisation 2) diabetes-specific 157 services received at podiatrist, 3) purchases of glucose lowering drugs. Thus, if a patient developed 158 transient T2D during chemotherapy treatment, it will only be an inclusion event if they purchase of 159 glucose lowering drugs. Individuals were classified as having T1D if they had received 160 prescriptions for insulin combined with a diagnosis of type 1 from a medical hospital department. Otherwise, diabetes was classified as type 2.<sup>23</sup> 161

- 162
- 163
- 164
- 165
- 166

It is made available under a CC-BY-NC-ND 4.0 International license .

#### 167 Statistical analysis

168 Descriptive data was presented as means with standard deviations (SD) for continuous variables and 169 proportions (n, %) for categorical variables. Crude incidence rates (number of T2D diagnoses by 170 person-time at risk) were calculated for the six groups (type of surgery  $\pm$  chemo), and characterised 171 by preoperative variables (sex, age, body mass index (BMI), smoking, alcohol status, American 172 Society of Anesthesiologists physical status classification score (ASA), and treatment with 173 radiotherapy in Rectal cancer patients). Unadjusted and adjusted Cox regression analyses were used 174 to calculate hazard ratios (HRs) for developing T2D after different types of surgery with and 175 without chemotherapy (using Right-No-Chemo as a reference group), after radiation therapy among 176 Rectal resected (using Rectal-No-Radiation as reference), and after overall type of surgery (All 177 Colon (ref) vs All Rectal). The adjusted analyses were performed stepwise by first adjusting for 178 year of surgery, age at surgery, sex and BMI (Model 1), then further adjusting ASA, smoking and 179 alcohol consumption (Model 2a), and lastly, further adjusting for chemotherapy (Model 2b) in the 180 analyses on radiation therapy and overall type of surgery

181

182 Finally, the impact of BMI on the risk of developing of T2D was investigated within each of the six

183 groups. BMI was categorized into 4 subgroups (18.5-24.9, 25-29.9, 30-34.9 and 35-39.9), and

underweight (BMI<18.5) or severely obese (BMI  $\ge$  40) subjects were excluded from these analyses

185 due to low numbers. For each group (type of surgery  $\pm$  chemotherapy), the HR for developing T2D

186 depending on BMI subgroups was calculated by using Cox regression analysis adjusted for age,

187 sex, year of surgery, and ASA score using normal weight (BMI:18.5-24.9) as the reference group.

188 A sensitivity analyses was performed restricting the inclusion period of surgery patients from 2001-

189 2018 to 2010-2018, as baseline information was complete from 2010.

190 All analyzes were conducted using STATA version 16 (STATA Corp., College Station, Tex.,

- 191 USA). P-value of P<0.05 was considered statistically significant. Results were presented with 95%</li>192 confidence interval (CI) when relevant.
- 193

194 **Results** 

## 195 **Baseline characteristics**

196 A total of 46,373 CRC patients without preoperatively recorded diabetes were found eligible for the

197 study (Figure 1) and were divided into six groups: 10,566 Right-No-Chemo (23%), 4,645 Right-

It is made available under a CC-BY-NC-ND 4.0 International license .

Chemo (10%), 10,151 Left-No-Chemo (22%), 5,257 Left-Chemo (11%), 9,618 Rectal-No-Chemo (21%) and 6,136 Rectal-Chemo (13%).

- 200 Compared with the Right, the Left and Rectal groups were younger, more often men, and less often
- 201 classified as ASA>II (Table 1). Those that had received chemotherapy were generally younger, less
- 202 often classified as ASA>II and as expected more often stage III/IV cancers than No-Chemo.
- 203

# 204 Incidence rates of diabetes

205 During the 245,466 person-years of follow up, 2,556 cases of T2D were diagnosed (10.4 per 1000 206 person-years) (Table 2) and the mean time to onset of T2D post-surgery spanned from 4.1-4.7 years 207 across the subgroups. The incidence rate (IR) of T2D was almost similar between the six groups 208 with the highest IR observed in the Left-No-Chemo group (IR 11.3 (95%CI: 10.4-12.2) per 1,000 209 person-years), and the lowest IR observed in the Rectal-No-Chemo group (IR 9.6 (95%CI: 8.8-210 10.4) per 1,000 person-years). Across all groups, the T2D IR was consistently higher in males than 211 in females, in patients with BMI  $\geq$ 25 compared with BMI of 18.5-24.9, and in ASA > I compared 212 with ASA score I (Table 2).

213

# Risk of developing T2D after different types of colorectal cancer surgery with and without chemotherapy

When compared with the Right-No-Chemo group, the other groups had similar and non-significant unadjusted hazard ratio (HR) of developing T2D (Table 3). In the adjusted analysis Rectal-No-Chemo was associated with a lower risk of T2D (HR 0.86 [95%CI 0.75-0.98]) compared with Right-No-Chemo. In the sub analysis comparing All Colon resected with All Rectal resected, the unadjusted and adjusted HR for developing T2D were significant lower for Rectal resected. Moreover, adjusting for cancer stage did not affect the results (Supplementary table 1).

222

# 223 Risk of developing T2D after radiation therapy among rectal resected patients

Radiation therapy in the rectal resected groups had no impact on the incidence rate of (Table 2), and

the unadjusted/adjusted HR of developing T2D was non-significant when comparing Rectal-No-

226 Radiation patients with Rectal-Radiation patients (Table 3).

It is made available under a CC-BY-NC-ND 4.0 International license .

#### 228 The impact of BMI on development of T2D

BMI had a strong association with T2D regardless of surgical resection and treatment with chemotherapy (Figure 2). The risk of developing T2D increased near twofold every time the BMI group increased one level, for example in the Right-No-Chemo group: HR 2.13 in BMI 25-30, HR 3.63 in BMI 30-35, HR 8.01 in BMI 35-40, compared with the reference BMI of 18.5-25. A similar pattern was observed within each of the other five groups, although a less pronounced impact of BMI was observed in the Left-No-Chemo group: HR 1.85 in 25-30, 2.93 in 30-35, 4.21 in 35-40 BMI group.

236

# 237 Discussion

This national cohort study demonstrated an IR of developing T2D after CRC surgery similar to previous studies. <sup>5,11</sup> Comparing resection types, rectal cancer resected patients had a slightly lower risk of developing T2D when compared to colon cancer resected patients. Treatment with chemotherapy had no impact on T2D risk in any of the resection groups, and radiation therapy did not affect T2D risk either.

Within each of the six groups (different types of surgery with and without chemotherapy), BMI was strongly associated to developing T2D, the risk increased almost twofold every time the BMI group increased one level.

246 Only few studies have examined the risk of developing T2D after different kinds of colonic- and 247 rectal surgical procedures, and in contrast to the present study the following studies were not able to 248 adjust for several confounders incl. preoperative BMI. Jensen et al. found a higher risk of T2D after 249 the left-sided compared with the right-sided colonic resections, but, in contrast to the current study, 250 patients operated for both non-malignant as well as malignant diseases were included. <sup>15</sup> In support 251 of side-specific effect of colonic resections, Wu et al. investigated a population of non-CRC 252 patients and showed that right-sided and transversal colonic resections were associated with a reduced risk of T2D development compared with patients without colectomy.<sup>16</sup> In contrast to both 253 254 the abovementioned studies the most recent epidemiological study found an increased T2D risk 255 after colectomy compared with small bowel resection in non-cancer patients, but when stratifying by resection type, they found no difference in T2D risk.<sup>24</sup> 256

In Denmark, the overall T2D prevalence is 6.9%<sup>25</sup>, lower than the global average in 2021 (10.5%)

and also falls below the estimate of high-income countries (11.1%).<sup>26</sup> Similarly, the obesity rate of

259 20% aligns with other Scandinavian countries and is below that of most high-income nations.<sup>27</sup>

It is made available under a CC-BY-NC-ND 4.0 International license .

260

Obesity is one of the predominant factors in the development of T2D<sup>28-30</sup>, and the linear increase in new onset T2D with increased BMI reported in this study is well described in the literature. <sup>31</sup> It is important to emphasize that only pre-operative BMI was included in the adjustments as postsurgery BMI information was not available and accordingly, weight trajectories after surgery could not be included in the analyses. It's still unknown how body weight and body composition changes after different types of CRC resection, and thus it is not clear whether changes in weight in any groups play a role in diabetes development.

268

Like our findings, Jensen et al. and Wu et al. found a tendency towards a decreased risk of T2D after rectal resection, although these findings were not statistically significant in the previous studies. <sup>15,16</sup> Further studies are needed to elucidate the potential mechanism behind this finding.

We found no impact of treatment with chemotherapy on T2D risk, which was a bit surprising. Prior studies indicated that treatment with chemotherapy may induce hyperglycemia, and especially the combined use of chemotherapy and glucocorticoid, administered to alleviate side-effects of chemotherapy, may have synergistic effects on later diabetes risk.<sup>32</sup>

276 In the study period of the present study, different types of chemotherapy have been part of the standard treatment of colon and rectum cancer respectively, and knowledge regarding the specific 277 effects of each drug on glucose homeostasis is sparse.<sup>33</sup> In most cases CRC patients included in the 278 study, will however have been treated with the chemotherapy 5-Flourouracil.<sup>12</sup> In a recent study a 279 significant increase in glycemic variability, a precursor of T2D development, was found in non-280 281 diabetic early-stage colon cancer patients during 5-Flourouracil and Capecitabine chemotherapy treatment. <sup>34</sup>. Moreover, Feng et al. showed a 10% increased risk of developing T2D in CRC 282 283 patients during and after treatment with adjuvant 5- Flourouracil. They argued that 5-Flourouracil could induce toxicity in B-cells leading to hyperglycaemia. <sup>12</sup> Similarly, Lee et al revealed an 284 impairment in glucose homeostasis in both breast cancer and CRC patients treated with 285 chemotherapy and glucocorticoid following treatment.<sup>13</sup> Nonetheless 65% of the newly diagnosed 286 287 T2D cases remitted 6 months after discontinuation of chemotherapy, suggesting that chemotherapy is a reversible diabetogenic factor.<sup>13</sup> Thus, in summary, treatment with chemotherapy may 288 289 primarily induce transient effects on glucose homeostasis in CRC patients. In contrast to the lack of influence of chemotherapy treatment, it was not surprising that radiation therapy had no impact on 290 291 diabetes risk in our study.

It is made available under a CC-BY-NC-ND 4.0 International license .

292

Due to the strong negative prognostic effects of comorbidity with T2D on CRC outcomes, identifying CRC patients at increased risk of developing T2D is of great clinical importance. Our study did not support a role of cancer surgery with left-sided colonic resection or treatment with chemotherapy in T2D development in CRC survivors. However, in line with existing literature we found BMI to be strongly associated with T2D development.

298

A core strength of the present study is the use of a nationwide database, allowing inclusion of large numbers of CRC patients treated with different types of CRC resections, providing valid real-life data regarding with close to complete coverage and long-term follow-up and a register-based approach to identify individuals with T2D. We were able to adjust for several confounders such as BMI, alcohol consumption and smoking, which has been a limitation in previous studies.<sup>15,16</sup>

304 The limitation of the present study includes that information on BMI and other risk factors for 305 developing T2D were only available preoperatively, eliminating the possibility of exploring an impact of BMI trajectories after cancer treatment until the T2D diagnosis.<sup>35</sup> Secondly, information 306 307 on dose, length of treatment and type of chemotherapy were not available. Thirdly, information on 308 physical activity, diet, medication, and comorbidities, apart from the ASA score, were not available. 309 In addition, our findings are limited by the register-based data collection method. Clinical well-310 designed mechanistic investigations are warranted to establish whether left-sided CRC resection per 311 se drives metabolic alterations leading to an increased risk of T2D.

312

In summary, we report a slightly increased risk of developing T2D after CRC treatment with colonic resection compared with rectal resection, whereas chemotherapy had no impact on new onset T2D. Within each surgical subgroup, BMI at time of surgery was strongly associated to developing T2D. This study suggests that postoperative diabetes screening should be prioritized in CRC survivors with overweight/obesity regardless of type of colorectal cancer treatment applied.

- 318
- 319 Acknowledgement

320 The authors thank the DCCG for access to data and Danish Cancer Society for support.

It is made available under a CC-BY-NC-ND 4.0 International license .

#### 322 Funding

- 323 This work was supported by the Danish Diabetes Association and the Danish Diabetes Academy,
- 324 which is funded by the Novo Nordisk Foundation, grant number *NNF17SA0031406*.
- 325 The Centre for Physical Activity Research (CFAS) is supported by TrygFonden (grants ID 101390,
- 326 ID 20045, and ID 125132).
- 327

# 328 **Ethics approval**

- 329 According to Danish law and the Committee on Health Research Ethics in the Central Denmark
- 330 Region, the study required no ethical approval because it was based on secondary use of register
- data for research purposes. This committee also waived patient consent for the use of register data.
- 332 The study was approved by the Central Region Denmark (file no. 1-16-02-304-19).
- 333

# **334 Patient consent for publication**

- 335 Not applicable
- 336

## 337 Contributors

Conceptualization, TL and LLL. Methodology, TL, LLL, CK, TIAS, MSS and JFC. Access to and
verified the raw data and formal analysis TL and SBG. Resources, TL, LLL. Writing - Original
draft CK, TL, LLL, MSS and SM. Writing – Review and editing, all authors contributed.

341 All authors approved the final version for publication, and LLL had final responsibility for the 342 decision to submit.

343

## 344 **Declaration of interests**

345 The authors disclose no conflicts.

346

# 347 Data sharing

Anonymized data will be made available upon reasonable request for academic use and within the limitations of the informed consent. Requests should be made to last author tinlaurb@rm.dk. Due to the Danish law it is not possible to make national health registers available, but on request we would like to collaborate and discuss reasonable access to data.

- 352
- 353

- 0.5.4

- -

389		
390		
391	Refe	rence
392	1.	Araghi M, Soerjomataram I, Jenkins M, et al. Global trends in colorectal cancer mortality:
393		projections to the year 2035. Int J Cancer. 2019;144(12):2992-3000. doi:10.1002/ijc.32055
394	2.	Arnold M, Sierra MS, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global patterns and
395		trends in colorectal cancer incidence and mortality. Gut. 2017;66(4):683-691.
396		doi:10.1136/gutjnl-2015-310912
397	3.	González N, Prieto I, del Puerto-Nevado L, et al. 2017 Update on the Relationship between
398		Diabetes and Colorectal Cancer: Epidemiology, Potential Molecular Mechanisms and
399		Therapeutic Implications. Vol 8.; 2017. www.impactjournals.com/oncotarget
400	4.	Mills KT, Bellows CF, Hoffman AE, Kelly TN, Gagliardi G. Diabetes mellitus and
401		colorectal cancer prognosis: A meta-analysis. Dis Colon Rectum. 2013;56(11):1304-1319.
402		doi:10.1097/DCR.0b013e3182a479f9
403	5.	Singh S, Earle CC, Bae SJ, et al. Incidence of Diabetes in Colorectal Cancer Survivors. J
404		Natl Cancer Inst. 2016;108(6). doi:10.1093/jnci/djv402
405	6.	Xiao Y, Wang H, Tang Y, et al. Increased risk of diabetes in cancer survivors: a pooled
406		analysis of 13 population-based cohort studies. ESMO Open. 2021;6(4).
407	_	doi:10.1016/j.esmoop.2021.100218
408	7.	Colorectal D, Nordcan 2019. 5-Year Age-Standardised Relative Survival (%), Males and
409		<i>Females</i> . Accessed September 12, 2022.
410		"https://nordcan.iarc.fr/en/dataviz/survival?cancers=520&set_scale=0&sexes=1_2&populati
411	0	ons=208"" has been copied into your clipboard
412	8.	Nano J, Dhana K, Asllanaj E, et al. Trajectories of BMI Before Diagnosis of Type 2 Disbeton The Betterdam Study. <i>Obscie</i> , 2020;28(6):1140, 1156, doi:10.1002/sby.22802
413 414	9.	Diabetes: The Rotterdam Study. <i>Obesity</i> . 2020;28(6):1149-1156. doi:10.1002/oby.22802 Maddatu J, Anderson-Baucum E, Evans-Molina C. Smoking and the risk of type 2 diabetes.
414	9.	<i>Translational Research</i> . 2017;184:101-107. doi:10.1016/j.trsl.2017.02.004
415	10.	Lega IC, Lipscombe LL. Review: Diabetes, Obesity, and Cancer-Pathophysiology and
417	10.	Clinical Implications. <i>Endocr Rev.</i> 2020;41(1). doi:10.1210/endrev/bnz014
418	11.	Jo A, Scarton L, O'Neal LTJ, et al. New onset of type 2 diabetes as a complication after
419	11.	cancer diagnosis: A systematic review. <i>Cancer Med.</i> 2021;10(2):439-446.
420		doi:10.1002/cam4.3666
421	12.	Feng JP, Yuan XL, Li M, et al. Secondary diabetes associated with 5-fluorouracil-based
422		chemotherapy regimens in non-diabetic patients with colorectal cancer: Results from a
423		single-centre cohort study. Colorectal Disease. 2013;15(1):27-33. doi:10.1111/j.1463-
424		1318.2012.03097.x
425	13.	Lee EK, Koo B, Hwangbo Y, et al. Incidence and disease course of new-onset diabetes
426		mellitus in breast and colorectal cancer patients undergoing chemotherapy: A prospective
427		multicenter cohort study. Diabetes Res Clin Pract. 2021;174.
428		doi:10.1016/j.diabres.2021.108751
429	14.	Jeong Y, Han HS, Lee HD, et al. A pilot study evaluating steroid-induced diabetes after
430		antiemetic dexamethasone therapy in chemotherapy-treated cancer patients. Cancer Res
431		Treat. 2016;48(4):1429-1437. doi:10.4143/crt.2015.464
432	15.	Jensen AB, Sørensen TI, Pedersen O, Jess T, Brunak S, Allin KH. Increase in clinically
433		recorded type 2 diabetes after colectomy. Published online 2018.
434		doi:10.7554/eLife.37420.001

435	16.	Wu CC, Lee CH, Hsu TW, et al. Is colectomy associated with the risk of type 2 diabetes in
436		patients without colorectal cancer? A population-based cohort study. J Clin Med.
437		2021;10(22). doi:10.3390/jcm10225313
438	17.	Holst JJ, Gribble F, Horowitz M, Rayner CK. Roles of the gut in glucose homeostasis.
439		Diabetes Care. 2016;39(6):884-892. doi:10.2337/dc16-0351
440	18.	Lin XH, Jiang JK, Luo JC, et al. The long term microbiota and metabolic status in patients
441		with colorectal cancer after curative colon surgery. PLoS One. 2019;14(6).
442		doi:10.1371/journal.pone.0218436
443	19.	Palnæs Hansen C, Andreasen JJ, Holst JJ. The release of gastric inhibitory peptide, glucagon-
444		like peptide-I, and insulin after oral glucose test in colectomized subjects. Scand J
445		Gastroenterol. 1997;32(5):473-477. doi:10.3109/00365529709025084
446	20.	Pedersen CB, Gøtzsche H, Møller JØ, Mortensen PB, Med Bull D. The Danish Civil
447		Registration System A Cohort of Eight Million Persons.
448	21.	Klein MF, Gögenur I, Ingeholm P, et al. Validation of the Danish Colorectal Cancer Group
449		(DCCG.dk) database – on behalf of the Danish Colorectal Cancer Group. <i>Colorectal</i>
450		Disease. Published online 2020. doi:10.1111/codi.15352
451	22.	Carstensen B, Kristensen JK, Marcussen MM, Borch-Johnsen K. The national diabetes
452		register. Scand J Public Health. 2011;39(7):58-61. doi:10.1177/1403494811404278
453	23.	Isaksen AA, Sandbæk A, Bjerg L. Validation of Register-Based Diabetes Classifiers in
454		Danish Data. Clin Epidemiol. 2023;15:569-581. doi:10.2147/CLEP.S407019
455	24.	Allin KH, Agrawal M, Iversen AT, Antonsen J, Villumsen M, Jess T. The Risk of Type 2
456		Diabetes in Patients With Inflammatory Bowel Disease After Bowel Resections: A
457		Nationwide Cohort Study. Gastro Hep Advances. 2022;1(5):777-784.
458		doi:10.1016/j.gastha.2022.06.007
459	25.	Diabetesforeningen. Nøgletal om diabetespopulation Type 2 2. Kvartal 2023.
460		https://www.diabetestal.nu. Published November 17, 2023. Accessed December 20, 2023.
461		https://www.diabetestal.nu
462	26.	Sun H, Saeedi P, Karuranga S, et al. IDF Diabetes Atlas: Global, regional and country-level
463		diabetes prevalence estimates for 2021 and projections for 2045. Diabetes Res Clin Pract.
464		2022;183. doi:10.1016/j.diabres.2021.109119
465	27.	Hannah Ritchie, Max Roser. Obesity. Our World in Data. Published September 11, 2017.
466		Accessed December 20, 2023. https://ourworldindata.org/obesity
467	28.	Wang Y, Rimm EB, Stampfer MJ, Willett WC, Hu FB. Comparison of Abdominal Adiposity
468		and Overall Obesity in Predicting Risk of Type 2 Diabetes among Men 1-3.; 2005.
469		https://academic.oup.com/ajcn/article/81/3/555/4648892
470	29.	Hu Y, Bhupathiraju SN, de Koning L, Hu FB. Duration of obesity and overweight and risk of
471		type 2 diabetes among US women. <i>Obesity</i> . 2014;22(10):2267-2273. doi:10.1002/oby.20851
472	30.	Lee DH, Keum NN, Hu FB, et al. Comparison of the association of predicted fat mass, body
473		mass index, and other obesity indicators with type 2 diabetes risk: two large prospective
474		studies in US men and women. Eur J Epidemiol. 2018;33(11):1113-1123.
475		doi:10.1007/s10654-018-0433-5
476	31.	Easson Karin A, Jon E, Martin A, et al. Body mass index in adolescence, risk of type 2
477		diabetes and associated complications: A nationwide cohort study of men. Published online
478		2022. doi:10.1016/j
479	32.	Hwangbo Y, Kang D, Kang M, et al. Incidence of diabetes after cancer development a
480		Korean national cohort study. JAMA Oncol. 2018;4(8):1099-1105.
481		doi:10.1001/jamaoncol.2018.1684

- 482 33. Ariaans G, de Jong S, Gietema JA, Lefrandt JD, de Vries EGE, Jalving M. Cancer-drug
  483 induced insulin resistance: Innocent bystander or unusual suspect. *Cancer Treat Rev.*484 2015;41(4):376-384. doi:10.1016/j.ctrv.2015.02.007
- 485 34. Mandolfo NR, Berger AM, Struwe LA, et al. Glycemic Variability in Patients With Stage II–
  486 III Colon Cancer Treated With Surgery and Adjuvant Chemotherapy. *Oncol Nurs Forum*.
- 487 2022;49(6):571-584. doi:10.1188/22.ONF.571-584
- 488 35. Winkels RM, Snetselaar T, Adriaans A, et al. Changes in body weight in patients with
  489 colorectal cancer treated with surgery and adjuvant chemotherapy: An observational study.
- 490 *Cancer Treat Res Commun.* 2016;9:111-115. doi:10.1016/j.ctarc.2016.09.002
- 491
- 492
- 493

It is made available under a CC-BY-NC-ND 4.0 International license .

#### 494

	Right-sided resection (Right) (N=15,211)			section (Left) 5,408)		ection (Rectal) 15,754)
	Right-No- Chemo	Right-Chemo	Left-No-Chemo	Left-Chemo	Rectal-No- Chemo	Rectal-Chemo
All patients, n (%)	10,566 (23%)	4,645 (10%)	10,151 (22%)	5,257 (11%)	9,618 (21%)	6,136 (13%)
Sex, n (%)						
Male	4,338 (41%)	2,126 (46%)	5,450 (54%)	2,834 (54%)	5,743 (60%)	3,745 (61%)
Female	6,228 (59%)	2,519 (54%)	4,701 (46%)	2,423 (46%)	3,875 (40%)	2,391 (39%)
Age, year, mean (SD)	75.2 (10.0)	66.9 (10.1)	72.1 (10.7)	64.8 (10.1)	70.0 (10.7)	64.3 (10.1)
BMI, mean (SD)	25.0 (4.7)	25.4 (4.7)	25.7 (4.6)	25.8 (4.5)	25.6 (4.4)	25.6 (4.4)
BMI subgroups	23.0 (4.7)	25.4 (4.7)	23.7 (4.0)	23.8 (4.3)	23.0 (4.4)	25.0 (4.4)
<18.5	482 (4.6%)	114 (2.5%)	287 (2.8%)	97 (1.8%)	225 (2.3%)	143 (2.3%)
18.5-24.9	4,183 (40%)	1,907 (41%)	3,638 (36%)	2,004 (38%)	3,693 (38%)	2,570 (42%)
25-29.9	2,671 (25%)	1,347 (29%)	2,945 (29%)	1,641 (31%)	3,021 (31%)	1,993 (32%)
30-34.9	814 (7.7%)	404 (8.7%)	961 (9%)	545 (10%)	889 (9.2%)	611 (10%)
35-39.9	194 (1.8%)	90 (1.9%)	214 (2.1%)	135 (2.6%)	171 (1.8%)	132 (2.2%)
>40	62 (0.6%)	34 (0.7%)	69 (0.7%)	39 (0.7%)	60 (0.6%)	30 (0.5%)
Missing	2,160 (20%)	749 (16%)	2,037 (20%)	796 (15%)	1,559 (16%)	657 (11%)
Smoking, n (%)	2,100 (2070)	747 (10/0)	2,037 (2070)	750 (1570)	1,557 (1070)	057 (1170)
Never	3,132 (30%)	1,533 (33%)	3,030 (30%)	1.804 (34%)	2,828 (29%)	2,014 (33%)
Current	1,671 (16%)	791 (17%)	1,486 (15%)	821 (16%)	1,679 (17%)	1,305 (21%)
Former	3,376 (32%)	1,465 (32%)	3,415 (34%)	1,700 (32%)	3,421 (36%)	2,021(33%)
Missing	2,387 (22%)	856 (18%)	2,220 (21%)	932 (18%)	1,690 (18%)	796 (13%)
Alcohol <sup>a</sup> , n (%)	2,387 (2270)	0.00 (10%)	2,220 (2170)	932 (10%)	1,090 (1070)	790 (1370)
1-14	4,819 (46%)	2,342 (51%)	4,803 (47%)	2,771 (53%)	4,886 (51%)	3,399 (55%)
14-21	478 (5%)	2,342 (31%)	618 (6%)	333 (6%)	711 (7%)	494 (8%)
>21	433 (4%)	256 (6%)	593 (6%)	323 (6%)	671 (7%)	412 (7%)
None	2,269 (21%)	889 (19%)	1,722 (17%)	872 (17%)	1,446 (15%)	1,006 (16%)
Missing	2,209 (21%)	895 (19%)	2,415 (24%)	958 (18%)	1,440 (13%)	825 (13%)
ASA score <sup>b</sup> , n (%)	2,307 (24%)	895 (19%)	2,413 (24%)	938 (18%)	1,904 (20%)	823 (15%)
Healthy (=I)	1,633 (15%)	1,331 (29%)	2,185 (22%)	1,735 (33%)	2,541 (26%)	2,082 (34%)
Mild (=II)	5,457 (52%)	2,596 (56%)	5,299 (51%)	2,857 (54%)	5,265 (55%)	3,415 (56%)
$\frac{\text{Nild}(=I)}{\text{Sick}(=>II)}$						
Sick (=>11) Missing	3,160 (30%) 316 (3%)	613 (13%) 105 (2%)	2,442 (24%) 295 (3%)	548 (11%) 117 (2%)	1,653 (17%) 159 (2%)	557 (9%) 82 (1%)
Screening detected	770 (7%)	299 (6%)	1,077 (11%)	457 (9%)		394 (6%)
screening detected tumor, n (%)	//0(/%)	299 (0%)	1,077 (11%)	437 (9%)	664 (7%)	394 (0%)
UICC stage <sup>c</sup> , n (%)						
I/II	7,002 (66%)	674 (15%)	7,339 (72%)	745 (14%)	5,940 (62%)	420 (7%)
III/IV	3,330 (32%)	3,504 (75%)	2,506 (25%)	3,989 (76%)	2,246 (23%)	2,471 (40%)
Unknown	234 (2%)	467 (10%)	306 (3%)	523 (10%)	1,432 (15%)	3,245 (53%)
Radiation, n (%)			200 (270)		1,157 (12%)	2,983 (49%)

Chemo: Chemotherapy

<sup>a</sup> Alcohol items per week

<sup>b</sup> The American Society of Anesthesiologist score: I: Healthy, but with CRC, III: Mild systemic disease without substantial functional limitations, >II: Severe systemic disease, includes ASA stage III, IV, V, VI

<sup>c</sup> UICC stage, Union of International Cancer Control, Stage I: T1 or T2, Stage II: T3 or T4, Stage III: N1 or N2, Stage IV:

Disseminated disease at time of diagnosis

495

496

It is made available under a CC-BY-NC-ND 4.0 International license .

It is made available under a CC-BY-NC-ND 4.0 International license .

#### 501

	Right-sided resection (Right) (N=15.211)			Left-sided resection (Left) (N=15.408)		Rectum resection (Rectal) (N=15,754)	
	Right-No- Chemo	Right-Chemo	Left-No- Chemo	Left-Chemo	Rectal-No- Chemo	Rectal-Chemo	
All patients, n	10,566	4,645	10,151	5,257	9,618	6,136	
T2D development		,		,	,	,	
Numbers	495	235	609	323	560	334	
Mean time, year (SD)	4.1 (3.4)	4.1 (3.6)	4.1 (3.5)	4.4 (3.6)	4.7 (3.7)	4.3 (3.5)	
Person-years	48,039	22,317	53,935	29,301	58,448	33,422	
Incidence rates	10.3 (9.4-11.2)	10.5 (9.3-12.0)	11.3 (10.4- 12.2)	11.0 (9.9-12.3)	9.6 (8.8-10.4)	10.0 (9.0-11.1)	
Sex							
Male	13 (11-15)	14 (12-16)	14 (12-15)	14 (12-16)	11 (10-12)	12 (11-14)	
Female	9 (8-10)	8 (7-10)	9 (8-10)	8 (7-10)	8 (7-9)	7 (6-8)	
Age							
<50	3 (1-8)	6 (3-11)	7 (5-12)	8 (5-12)	5 (3-8)	6 (4-10)	
50-64.9	12 (10-14)	13 (11-16)	11 (9-12)	10 (8-12)	10 (8-12)	10 (9-12)	
65-74.9	12 (11-14)	11 (9-14)	12 (11-14)	14 (12-17)	14 (12-17)	11 (10-13)	
<u>≥</u> 75	9 (8-10)	6 (4-9)	11 (10-13)	8 (6-12)	8 (6-12)	8 (5-11)	
BMI subgroups							
18.5-24.9	6 (5-7)	5 (4-7)	6 (5-8)	4 (3-5)	4 (4-5)	4 (3-6)	
25-29.9	13 (11-16)	11 (9-14)	13 (11-15)	12 (10-15)	11 (9-12)	12 (10-14)	
30-34.9	23 (18-28)	30 (23-40)	21 (17-25)	24 (19-30)	25 (21-30)	24 (19-30)	
35-39.9	51 (38-70)	53 (34-84)	32 (23-45)	34 (23-52)	30 (21-44)	31 (20-48)	
Missing	7 (6-9)	9 (6-12)	11 (9-12)	12 (10-16)	9 (8-12)	10 (8-14)	
Smoking							
Never	9 (8-11)	11 (9-14)	9 (8-11)	8 (7-10)	8 (7-10)	9 (7-11)	
Current	13 (10-15)	9 (7-13)	11 (9-14)	12 (10-16)	10 (8-12)	10 (7-12)	
Former	11 (10-13)	12 (10-15)	13 (11-15)	13 (11-15)	11 (9-12)	11 (9-13)	
Missing	8 (7-10)	9 (6-12)	11 (10-14)	12 (9-15)	9 (8-11)	11 (8-14)	
Alcohol <sup>a</sup>							
1-14	11 (9-12)	10 (8-12)	10 (9-12)	10 (9-12)	9 (8-10)	10 (8-11)	
14-21	9 (6-14)	7 (3-14)	9 (6-13)	10 (7-16)	8 (6-11)	9 (6-14)	
>21	10 (7-16)	16 (11-25)	14 (11-19)	12 (8-18)	11 (9-15)	13 (9-18)	
None	12 (10-14)	14 (10-18)	13 (11-16)	12 (9-16)	13 (11-15)	10 (7-13)	
Missing	9 (7-10)	10 (7-13)	12 (10-14)	12 (10-16)	10 (9-10)	10 (8-13)	
ASA score <sup>b</sup>						, , ,	
Healthy (=I)	7 (6-9)	5 (3-7)	7 (6-9)	7 (5-9)	5 (4-6)	6 (4-7)	
Mild (=II)	10 (9-12)	12 (11-15)	12 (11-13)	13 (11-15)	11 (10-12)	13 (11-14)	
Sick (=>II)	14 (12-17)	17 (13-24)	17 (12-17)	18 (14-25)	15 (12-18)	12 (8-17)	
Missing	6 (3-11)	15 (7-31)	13 (8-20)	11 (5-23)	9 (5-17)	10 (4-25)	
Radiation							
Yes			•	•	11 (9-13)	11 (9-13)	
No	•				9 (9-10)	10 (9-12)	

Table 2 Absolute incidence rates of type 2 diabetes (T2D) per 1000 person-years (95% CD) among colorectal cancer

Chemo: Chemotherapy

<sup>a</sup> Alcohol items per week

<sup>b</sup> The American Society of Anesthesiologist score: I: Healthy, but with CRC, III: Mild systemic disease without substantial functional limitations, >II: Severe systemic disease, includes ASA stage III, IV, V, VI

502

503

It is made available under a CC-BY-NC-ND 4.0 International license .

## 

	Unadjusted	-	Model 1		Model 2 <sup>(a/b)</sup>	
	HR (95%CI)	p-value	HR (95%CI)	p-value	HR (95%CI)	p-valu
Surgery and chemotherapy						
Right-No-Chemo	ref					
Right-Chemo	1.02 (0.87;1.19)	0.799	0.99 (0.83;1.17)	0.880	1.01 (0.85;1.20) <sup>a</sup>	0.88
Left-No-Chemo	1.10 (0.98;1.24)	0.112	0.92 (0.81;1.05)	0.228	0.94 (0.82;1.07) <sup>a</sup>	0.33
Left-Chemo	1.07 (0.93;1.23)	0.339	0.93 (0.79;1.09)	0.366	0.97 (0.83;1.14) <sup>a</sup>	0.70
Rectal-No-Chemo	0.94 (0.83;1.06)	0.317	0.82 (0.72;0.94)	0.004	0.86 (0.75;0.98) <sup>a</sup>	0.02
Rectal-Chemo	0.96 (0.84;1.11)	0.610	0.84 (0.72;0.99)	0.031	0.89 (0.76;1.03) <sup>a</sup>	0.12
Surgery and radiation therapy						
Rectal-No-Radiation	ref					
Rectal-Radiation	1.07 (0.93;1.24)	0.336	0.98 (0.85;1.13)	0.804	0.97 (0.84;1.12) <sup>b</sup>	0.69
Surgery						
All Colon	ref					
All Colon All Rectal Right: Right-sided colo No-Chemo: No chemo No-radiation: No radic All Colon: All right- a All Rectal: All rectal r	0.90 (0.83;0.98) onic resections; Left: therapy; Chemo: Che otherapy; Radiation: R nd left-sided colonic r	emotherapy Radiation ther resections wi	apy th and without chemo	otherapy		0.01
All Rectal Right: Right-sided cole No-Chemo: No chemo No-radiation: No radic All Colon: All right- a All Rectal: All rectal re Model 1: adjusted for y Model 2a: adjusted like	0.90 (0.83;0.98) onic resections; Left: therapy; Chemo: Che otherapy; Radiation: R nd left-sided colonic r esections with and wi year of surgery, age at e Model 1 and further	Left-sided cc emotherapy Radiation ther resections wi thout chemot t surgery, sex	blonic resections; Rec rapy th and without chemo therapy, and with and c, BMI	tal: Rectal re otherapy without rad	essections	
All Rectal Right: Right-sided cole No-Chemo: No chemo No-radiation: No radic All Colon: All right- a All Rectal: All rectal re Model 1: adjusted for Model 2a: adjusted lik of Anesthesiologist ph	0.90 (0.83;0.98) onic resections; Left: therapy; Chemo: Che otherapy; Radiation: R nd left-sided colonic r esections with and wi year of surgery, age at e Model 1 and further ysical scale, smoking	Left-sided cc emotherapy Radiation ther resections wi thout chemot t surgery, sex adjusted for and alcohol	blonic resections; Rec apy th and without chemo therapy, and with and a, BMI performance status b	tal: Rectal re otherapy without rad	essections	
All Rectal Right: Right-sided cole No-Chemo: No chemo No-radiation: No radic All Colon: All right- a All Rectal: All rectal re Model 1: adjusted for Model 2a: adjusted lik of Anesthesiologist ph	0.90 (0.83;0.98) onic resections; Left: therapy; Chemo: Che otherapy; Radiation: R nd left-sided colonic r esections with and wi year of surgery, age at e Model 1 and further ysical scale, smoking	Left-sided cc emotherapy Radiation ther resections wi thout chemot t surgery, sex adjusted for and alcohol	blonic resections; Rec apy th and without chemo therapy, and with and a, BMI performance status b	tal: Rectal re otherapy without rad	essections	
All Rectal Right: Right-sided cole No-Chemo: No chemo No-radiation: No radic All Colon: All right- a All Rectal: All rectal re Model 1: adjusted for y Model 2a: adjusted like	0.90 (0.83;0.98) onic resections; Left: therapy; Chemo: Che otherapy; Radiation: R nd left-sided colonic r esections with and wi year of surgery, age at e Model 1 and further ysical scale, smoking	Left-sided cc emotherapy Radiation ther resections wi thout chemot t surgery, sex adjusted for and alcohol	blonic resections; Rec apy th and without chemo therapy, and with and a, BMI performance status b	tal: Rectal re otherapy without rad	essections	
All Rectal Right: Right-sided cole No-Chemo: No chemo No-radiation: No radic All Colon: All right- a All Rectal: All rectal re Model 1: adjusted for Model 2a: adjusted lik of Anesthesiologist ph	0.90 (0.83;0.98) onic resections; Left: therapy; Chemo: Che otherapy; Radiation: R nd left-sided colonic r esections with and wi year of surgery, age at e Model 1 and further ysical scale, smoking	Left-sided cc emotherapy Radiation ther resections wi thout chemot t surgery, sex adjusted for and alcohol	blonic resections; Rec apy th and without chemo therapy, and with and a, BMI performance status b	tal: Rectal re otherapy without rad	essections	
All Rectal Right: Right-sided cole No-Chemo: No chemo No-radiation: No radic All Colon: All right- a All Rectal: All rectal re Model 1: adjusted for Model 2a: adjusted lik of Anesthesiologist ph	0.90 (0.83;0.98) onic resections; Left: therapy; Chemo: Che otherapy; Radiation: R nd left-sided colonic r esections with and wi year of surgery, age at e Model 1 and further ysical scale, smoking	Left-sided cc emotherapy Radiation ther resections wi thout chemot t surgery, sex adjusted for and alcohol	blonic resections; Rec apy th and without chemo therapy, and with and a, BMI performance status b	tal: Rectal re otherapy without rad	essections	
All Rectal Right: Right-sided cole No-Chemo: No chemo No-radiation: No radic All Colon: All right- a All Rectal: All rectal re Model 1: adjusted for Model 2a: adjusted lik of Anesthesiologist ph	0.90 (0.83;0.98) onic resections; Left: therapy; Chemo: Che otherapy; Radiation: R nd left-sided colonic r esections with and wi year of surgery, age at e Model 1 and further ysical scale, smoking	Left-sided cc emotherapy Radiation ther resections wi thout chemot t surgery, sex adjusted for and alcohol	blonic resections; Rec apy th and without chemo therapy, and with and a, BMI performance status b	tal: Rectal re otherapy without rad	essections	
All Rectal Right: Right-sided cole No-Chemo: No chemo No-radiation: No radic All Colon: All right- a All Rectal: All rectal re Model 1: adjusted for Model 2a: adjusted lik of Anesthesiologist ph	0.90 (0.83;0.98) onic resections; Left: therapy; Chemo: Che otherapy; Radiation: R nd left-sided colonic r esections with and wi year of surgery, age at e Model 1 and further ysical scale, smoking	Left-sided cc emotherapy Radiation ther resections wi thout chemot t surgery, sex adjusted for and alcohol	blonic resections; Rec apy th and without chemo therapy, and with and a, BMI performance status b	tal: Rectal re otherapy without rad	essections	
All Rectal Right: Right-sided cole No-Chemo: No chemo No-radiation: No radic All Colon: All right- a All Rectal: All rectal re Model 1: adjusted for Model 2a: adjusted lik of Anesthesiologist ph	0.90 (0.83;0.98) onic resections; Left: therapy; Chemo: Che otherapy; Radiation: R nd left-sided colonic r esections with and wi year of surgery, age at e Model 1 and further ysical scale, smoking	Left-sided cc emotherapy Radiation ther resections wi thout chemot t surgery, sex adjusted for and alcohol	blonic resections; Rec apy th and without chemo therapy, and with and a, BMI performance status b	tal: Rectal re otherapy without rad	essections	
All Rectal Right: Right-sided cole No-Chemo: No chemo No-radiation: No radic All Colon: All right- a All Rectal: All rectal re Model 1: adjusted for Model 2a: adjusted lik of Anesthesiologist ph	0.90 (0.83;0.98) onic resections; Left: therapy; Chemo: Che otherapy; Radiation: R nd left-sided colonic r esections with and wi year of surgery, age at e Model 1 and further ysical scale, smoking	Left-sided cc emotherapy Radiation ther resections wi thout chemot t surgery, sex adjusted for and alcohol	blonic resections; Rec apy th and without chemo therapy, and with and a, BMI performance status b	tal: Rectal re otherapy without rad	essections	an Society
All Rectal Right: Right-sided cole No-Chemo: No chemo No-radiation: No radic All Colon: All right- a All Rectal: All rectal re Model 1: adjusted for Model 2a: adjusted lik of Anesthesiologist ph	0.90 (0.83;0.98) onic resections; Left: therapy; Chemo: Che otherapy; Radiation: R nd left-sided colonic r esections with and wi year of surgery, age at e Model 1 and further ysical scale, smoking	Left-sided cc emotherapy Radiation ther resections wi thout chemot t surgery, sex adjusted for and alcohol	blonic resections; Rec apy th and without chemo therapy, and with and a, BMI performance status b	tal: Rectal re otherapy without rad	essections	
All Rectal Right: Right-sided cole No-Chemo: No chemo No-radiation: No radic All Colon: All right- a All Rectal: All rectal re Model 1: adjusted for Model 2a: adjusted lik of Anesthesiologist ph	0.90 (0.83;0.98) onic resections; Left: therapy; Chemo: Che otherapy; Radiation: R nd left-sided colonic r esections with and wi year of surgery, age at e Model 1 and further ysical scale, smoking	Left-sided cc emotherapy Radiation ther resections wi thout chemot t surgery, sex adjusted for and alcohol	blonic resections; Rec apy th and without chemo therapy, and with and a, BMI performance status b	tal: Rectal re otherapy without rad	essections	
All Rectal Right: Right-sided cole No-Chemo: No chemo No-radiation: No radic All Colon: All right- a All Rectal: All rectal re Model 1: adjusted for Model 2a: adjusted lik of Anesthesiologist ph	0.90 (0.83;0.98) onic resections; Left: therapy; Chemo: Che otherapy; Radiation: R nd left-sided colonic r esections with and wi year of surgery, age at e Model 1 and further ysical scale, smoking	Left-sided cc emotherapy Radiation ther resections wi thout chemot t surgery, sex adjusted for and alcohol	blonic resections; Rec apy th and without chemo therapy, and with and a, BMI performance status b	tal: Rectal re otherapy without rad	essections	
All Rectal Right: Right-sided cole No-Chemo: No chemo No-radiation: No radic All Colon: All right- a All Rectal: All rectal re Model 1: adjusted for Model 2a: adjusted lik of Anesthesiologist ph	0.90 (0.83;0.98) onic resections; Left: therapy; Chemo: Che otherapy; Radiation: R nd left-sided colonic r esections with and wi year of surgery, age at e Model 1 and further ysical scale, smoking	Left-sided cc emotherapy Radiation ther resections wi thout chemot t surgery, sex adjusted for and alcohol	blonic resections; Rec apy th and without chemo therapy, and with and a, BMI performance status b	tal: Rectal re otherapy without rad	essections	

It is made available under a CC-BY-NC-ND 4.0 International license .

Supplementary table 1. Likelihood of developing type 2 diabetes after different types of colorectal cancer surgery with and without oncological treatment, adjusted for UICC alone and in Model 1 and Model 2									
	Adjusted for UICC		Model 1 + UICC		Model 2+UICC				
	HR (95%CI)	p-value	HR (95%CI)	p-value	HR (95%CI)	p-value			
Surgery and chemotherapy									
Right-No-Chemo	ref								
Right-Chemo	0.98 (0.83;1.15)	0.788	0.93 (0.78;1.11)	0.441	0.97 (0.81;1.16)	0.731			
Left-No-Chemo	1.11 (0.98;1.24)	0.097	0.93 (0.81;1.06)	0.269	0.94 (0.83;1.07)	0.374			
Left-Chemo	1.03 (0.89;1.19)	0.730	0.88 (0.74;1.03)	0.120	0.93 (0.79;1.09)	0.373			
Rectal-No-Chemo	0.93 (0.82;1.05)	0.225	0.81 (0.71;0.93)	0.002	0.85 (0.74;0.97)	0.018			
Rectal-Chemo	0.89 (0.76;1.04)	0.139	0.76 (0.64;0.90)	0.002	0.82 (0.69;0.97)	0.022			

Right: Right-sided colonic resections; Left: Left-sided colonic resections; Rectal: Rectal resections No-Chemo: No chemotherapy; Chemo: Chemotherapy

All Colon: All right- and left-sided colonic resections with and without chemotherapy All Rectal: All rectal resections with and without chemotherapy, and with and without radiation therapy

Model 1: adjusted for year of surgery, age at surgery, sex, BMI Model 2: adjusted like Model 1 and further adjusted for performance status before surgery assessed by American Society of Anesthesiologist physical scale, smoking and alcohol

It is made available under a CC-BY-NC-ND 4.0 International license .

# 550 Figure legends

551 **Figure 1:** Flowchart of the study.

- 553 **Figure 2**: Likelihood of developing type 2 diabetes depending on BMI subgroups (using normal
- weight, BMI:18.5-25 as reference) after different types of colorectal cancer surgery with and
- 555 without chemotherapy.

It is made available under a CC-BY-NC-ND 4.0 International license .





Figure 1: Flowchart of the study

T2D: New-onset of type 2 diabetes

Right: Right-sided colonic resections; Left: Left-sided colonic resections; Rectal: Rectal recestions No-chemo: No chemotherapy; Chemo: Chemotherapy

It is made available under a CC-BY-NC-ND 4.0 International license .



Surgery, Chemotherapy and BMI

Figure 2: Likelihood of developing type 2 diabetes depending on BMI subgroups (using normal weight, BMI:18.5-25 as reference) after different types of colorectal cancer surgery with and without chemotherapy.

<sup>6</sup>Hazard ratios were adjusted for age, sex, year of surgery and ASA score (performance status before surgery assessed by American Society of Anesthesiologist physical scale).